David H. Ilson

A phase II trial of interferon alpha‐2A, 5‐fluorouracil, and cisplatin in patients with advanced esophageal carcinoma

Ying Huang, R. Heelan, D. Kelsen, 1995, Cancer.

A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma

Laura H. Tang, M. Shah, M. Capanu, 2011, Investigational New Drugs.

195TiP GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)

J. Ajani, Y. Bang, Ruifeng Xu, 2020 .

198TiP SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first-line Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)

J. Ajani, Y. Bang, Ruifeng Xu, 2020 .